Skip to Main Content

Paper Details

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol
22
2023
CD, Crohn's disease, IBD, IBDs, Inflammatory Bowel Diseases, TNF, Ustekinumab, Vedolizumab, filgotinib, inflammatory bowel diseases, ozanimod, patients, tofacitinib, tumor necrosis factor, ulcerative colitis, ustekinumab, vedolizumab
Author NameAffiliation
Cesare HassanHumanitas University, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital
Alessandro RepiciHumanitas University, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital
Vipul JairathWestern University
Siddharth SinghUniversity of California San Diego
  • 1 - 4

Datasets

Release 1.2